Tag Archives: AbbVie

Trends

Is an HIV Vaccine on the horizon?

Posted on by John Santilli

Published January 3, 2016 in Managed Healthcare Executive Is an HIV Vaccine on the horizon? There’s good news in efforts to combat HIV/AIDs and hepatitis C (hep C, HCV). These viral diseases are now more vulnerable because of improved gene-based targeting and communications around exposure from surveillance programs. Some feel, however, that policymakers could do […]

Continue reading →
Uncategorized

John Santilli quoted in Modern Medicine: Olysio indication expanded for combo use with Sovaldi in hepatitis C

Posted on by John Santilli

“[Hepatitis C] is a very competitive market, as a number of companies are looking to compete with Gilead’s products due to the large population of patients and the high earnings potential for drug sales,” said John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries.  Read more here: http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/top-five-industry-challenges-2015?page=0,7

Continue reading →
Market Report

Hepatitis C and Specialty Pharmacy Market

Posted on by aprilgregory

Express Scripts Plans a Specialty Drug Price War over new hepatitis C treatments reports a recent Bloomberg News story. The news follows the release of Gilead’s Sovaldi (sofosbuvir), which reportedly costs $1,000 per pill. Express Scripts projects that Hepatitis C drug trend will grow by 168% by 2015, so employers and health plan payers are […]

Continue reading →